MiMedx Group, Inc.
MiMedx Group, Inc. (Nasdaq: MDXG) develops and markets biologic and other products used in wound care, burns and surgery. Its portfolio includes human placental tissue allografts, bovine collagen products and distributed wound-care products, serving clinicians and healthcare providers in hospitals, wound-care centers,… From the company’s description.
Over the twelve months to Sep 30, 2026, MiMedx Group, Inc. reported revenue of $303.73M, down 22.8% from a year earlier, and a net loss of $19.19M. Its operating margin was −8.3%, and operations generated $20.74M in cash. In fiscal 2025, it reported revenue of $418.63M, up 20.0% from fiscal 2024, and net income of $48.58M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MiMedx Group, Inc. does
In the company’s own words
MiMedx Group, Inc. (Nasdaq: MDXG) develops and markets biologic and other products used in wound care, burns and surgery. Its portfolio includes human placental tissue allografts, bovine collagen products and distributed wound-care products, serving clinicians and healthcare providers in hospitals, wound-care centers, physician offices, ambulatory surgery centers, nursing homes and federal facilities. Products include EPIFIX, EPICORD, EPIEFFECT and AMNIOFIX, as well as HELIOGEN, its bovine collagen matrix. The company’s commercial activities focus on Wound and Surgical applications: wound products address chronic and hard-to-heal wounds, while surgical products are used in procedures to support wound closure or protect and reinforce tissues. MiMedx processes donated placental tissue using its proprietary PURION process at facilities in Georgia and also obtains some products from third-party manufacturers. It broadened its portfolio beyond placental biologics in 2024 with a xenograft and subsequently added products through exclusive distribution agreements. By December 31, 2025, it had supplied several million allografts.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- MARIETTA, GA
- Fiscal year end
- December
- CIK
- 1376339
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MiMedx Group, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MiMedx Group, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MiMedx Group, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MiMedx Group, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MiMedx Group, Inc.'s last four quarterly filings that the numbers alone won't show?”